Antiphospholipid syndrome (Sapporo/Sydney criteria) (also searched with possessive/alternate eponym spelling where applicable, ICD-10: D68.61) is a systemic autoimmune disorder characterized by recurrent arterial, venous, or microvascular thrombosis and/or pregnancy morbidity in the setting of persistent circulating antiphospholipid antibodies (aPL), including lupus anticoagulant (LA), moderate-to-high titer anticardiolipin (aCL) antibodies, or anti-$\beta_2$-glycoprotein I ($\beta_2$GPI) antibodies 1, 2. As the most common acquired thrombophilia, the syndrome can present as an isolated primary condition or secondary to underlying connective tissue diseases such as systemic lupus erythematosus 3, 5. Diagnosis is established by fulfilling international consensus classification criteria requiring the concordant presence of at least one clinical manifestation and at least one laboratory abnormality confirmed on repeat testing at least 12 weeks apart 1, 4. First-line management centers on lifelong vitamin K antagonist therapy for unprovoked thrombotic events and combined low-dose aspirin with prophylactic low-molecular-weight heparin for obstetric phenotypes 2, 6.

Etiology & Risk Factors

  • Primary vs. Secondary Form: Can occur as primary antiphospholipid syndrome in the absence of other autoimmune diseases, or secondary antiphospholipid syndrome when associated with systemic lupus erythematosus (seen in 30% to 40% of lupus patients), Sjögren syndrome, or rheumatoid arthritis 2, 5.
  • Genetic Susceptibility: Strongly associated with human leukocyte antigen (HLA) class II alleles, notably the HLA-DRB1*04, HLA-DRB1*07, and HLA-DQB1 loci, which predispose individuals to aberrant immune responses against phospholipid-binding plasma proteins 4.
  • Infectious Triggers: Viral and bacterial infections (e.g., cytomegalovirus, Epstein-Barr virus, hepatitis C, syphilis) can trigger transient or persistent aPL production via molecular mimicry or by inducing structural modifications in $\beta_2$-glycoprotein I 4, 7.
  • Coexisting Cardiovascular Risk Factors: Traditional pro-thrombotic drivers—including cigarette smoking, systemic hypertension, hyperlipidemia, obesity, oral contraceptive use, and surgical immobilization—act synergistically with aPL profiles to exponentially increase overall thrombotic risk 2.
  • Antibody Profile Risk Stratification: Triple positivity (presence of lupus anticoagulant, anticardiolipin antibodies, and anti-$\beta_2$GPI antibodies simultaneously) carries the highest risk for initial thrombosis, thrombotic recurrence, and pregnancy failure 2, 4.

Pathophysiology

The pathogenesis of antiphospholipid syndrome centers on the autoantibody-mediated breakdown of vascular endothelial homeostasis and activation of cellular components within the hemostatic and inflammatory cascades 4, 5. Circulating autoantibodies—predominantly directed against domain I of $\beta_2$-glycoprotein I ($\beta_2$GPI), a plasma protein that binds anionic phospholipids—interact with cellular membrane receptors including annexin A2, Toll-like receptors (TLR4 and TLR8), and apolipoprotein E receptor 2 on endothelial cells, monocytes, neutrophils, and platelets 3, 4. This binding triggers intracellular signaling cascades that upregulate tissue factor expression, stimulate endothelial adhesion molecules (such as VCAM-1, ICAM-1, and E-selectin), promote platelet aggregation, and induce neutrophil extracellular trap (NET) formation 4, 5. Concurrently, aPL directly activate the complement cascade via both the classical and alternative pathways, generating anaphylatoxins C3a and C5a and the membrane attack complex (C5b-9), which amplifies endothelial injury and tissue ischemia 4. In the microvasculature and placenta, this pro-thrombotic and pro-inflammatory milieu leads to widespread microthrombosis, impaired trophoblast invasion, defective spiral artery remodeling, and subsequent placental insufficiency or tissue infarction 4, 6.

Antiphospholipid syndrome (Sapporo/Sydney criteria) — Pathophysiological Cascade & Clinical Flowchart 1 Primary Autoimmune Trigger Loss of immune tolerance leading to generation of autoantibodies against phospholipid-binding proteins (e.g., beta-2-glycoprotein I) 2 Cellular & Endothelial Activation Antiphospholipid antibodies bind receptors on endothelial cells, platelets, and monocytes, triggering pro-inflammatory and pro-coagulant cascades 3 Vascular & Placental Microthrombosis Endothelial damage, complement activation, and platelet aggregation result in arterial, venous, and placental vessel occlusion 4 Cardinal Clinical Manifestations Presentation with deep vein thrombosis, pulmonary embolism, stroke, or recurrent early and late pregnancy losses 5 Therapeutic Target & Anticoagulation Prevention of recurrent thrombotic events via long-term vitamin K antagonism, antiplatelet therapy, and specialized obstetric management

Clinical Presentation & Classic Clinical Signs

  • History & Cardinal Symptoms: Patients frequently present with unprovoked or recurrent venous thromboembolism (deep vein thrombosis of the lower extremities, pulmonary embolism), arterial thrombosis manifesting as ischemic stroke or transient ischemic attack at a young age (< 50 years), peripheral arterial occlusion, or catastrophic multiorgan failure 2, 3, 7. Obstetric manifestations include unexplained recurrent early miscarriages (three or more consecutive spontaneous losses before the 10th week of gestation), fetal demise after the 10th week, or severe placental dysfunction resulting in early-onset pre-eclampsia, intrauterine growth restriction, or placental abruption 2, 4, 6.
  • Physical Examination & Named Clinical Signs: Cutaneous examination frequently reveals livedo reticularis (a net-like, reddish-blue mottling of the skin, particularly on the limbs and trunk) and painful cutaneous ulcerations or digital gangrene from microvascular occlusion 2. Cardiac auscultation may reveal new or changing murmurs indicative of valve thickening, non-bacterial thrombotic endocarditis (Libman-Sacks endocarditis), or secondary pulmonary hypertension 2. Neurological evaluation may uncover focal motor deficits, cognitive impairment, or chorea 2, 7. Laboratory screening often demonstrates incidental autoimmune thrombocytopenia or direct antiglobulin test (DAT)-positive hemolytic anemia 2.

Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Diagnostic Modality / Test Expected Clinical & Radiological / Laboratory Finding
Gold-Standard InvestigationCoagulation assays demonstrating lupus anticoagulant prolongation (e.g., dilute Russell's viper venom time [dRVVT] or aPTT-LA) that does not correct upon 1:1 mixing with normal pooled plasma, combined with solid-phase enzyme-linked immunosorbent assays (ELISA) showing moderate-to-high titer IgG/IgM anticardiolipin (> 40 GPL/MPL units or > 99th percentile) or anti-$\beta_2$GPI antibodies 1, 2, 4.
Laboratory PanelComplete blood count often showing mild-to-moderate thrombocytopenia (platelet count 50,000–150,000/µL); direct Coombs-positive hemolytic anemia; baseline coagulation parameters demonstrating prolonged screening clotting times corrected by excess phospholipid 2.
Imaging / Radiology (X-ray, US, CT, MRI)Compression duplex ultrasound revealing acute or chronic deep vein thrombosis; contrast-enhanced CT pulmonary angiography demonstrating filling defects in pulmonary arterial branches; brain MRI showing ischemic infarcts, white matter hyperintensities, or cerebral venous sinus thrombosis; echocardiography (transthoracic and transesophageal) identifying valvular thickening, vegetations (Libman-Sacks), or chamber enlargement 2, 3.
ECG / Histopathology / ProceduralElectrocardiogram showing sinus tachycardia, signs of right ventricular strain (in pulmonary embolism), or evidence of prior myocardial infarction; renal biopsy demonstrating thrombotic microangiopathy, fibrous intimal hyperplasia, and focal cortical atrophy (APS nephropathy); histopathological examination of placental tissue showing infarction, decidual vasculopathy, and thrombi in spiral arteries 2, 4, 6.

Staging, Classification & Clinical Scoring Systems

Criterion / Stage / Score Component Clinical Threshold, Points & Management Implication
Sapporo/Sydney Classification Criteria (Clinical)Requires at least one clinical event: (1) Vascular thrombosis (arterial, venous, or small vessel confirmed by imaging or histopathology); or (2) Pregnancy morbidity (one or more unexplained fetal deaths at > 10 weeks gestation, one or more premature births before 34 weeks due to severe pre-eclampsia/placental insufficiency, or three or more unexplained consecutive spontaneous abortions before 10 weeks) 1, 4.
Sapporo/Sydney Classification Criteria (Laboratory)Requires at least one laboratory finding: (1) Lupus anticoagulant present on two or more occasions at least 12 weeks apart; (2) Anticardiolipin IgG or IgM in medium/high titer (> 40 GPL/MPL or > 99th percentile) on two or more occasions at least 12 weeks apart; or (3) Anti-$\beta_2$-glycoprotein I IgG or IgM (> 99th percentile) on two or more occasions at least 12 weeks apart 1, 4.
Catastrophic APS (CAPS) Diagnostic CriteriaDefinite CAPS requires: (1) Involvement of three or more organs/tissues/systems; (2) Development of manifestations simultaneously or in less than a week; (3) Confirmation by histopathology of small vessel occlusion in at least one organ; and (4) Laboratory confirmation of aPL presence. Requires emergency multimodal triple therapy 7.
Global Antiphospholipid Syndrome Score (GAPSS)Risk stratification model scoring traditional cardiovascular risk factors, aPL profile (lupus anticoagulant, high-titer aCL, anti-$\beta_2$GPI), and IgG/IgM isotype. Higher scores predict elevated risk of first or recurrent thrombotic events, guiding decisions on primary prophylaxis 2, 4.

Differential Diagnosis

Differential Condition Distinguishing Clinical, Biochemical & Imaging Features
Hereditary ThrombophiliasFactor V Leiden mutation, prothrombin gene G20210A mutation, protein C/S deficiency, or antithrombin deficiency. Distinguished by absence of persistent aPL antibodies and typical familial inheritance patterns 3.
Thrombotic Thrombocytopenic Purpura (TTP)Marked microangiopathic hemolytic anemia, severe thrombocytopenia, and fluctuating neurological signs with normal or mildly elevated coagulation parameters. Characterized by profound ADAMTS13 deficiency (< 10 activity) rather than aPL 7.
Systemic Lupus Erythematosus (without aPL)Presents with multi-organ involvement (malar rash, serositis, glomerulonephritis, antinuclear antibodies, anti-dsDNA), but lacks sustained high-titer antiphospholipid antibodies and classic APS-associated large vessel thrombosis 2, 5.
Malignancy-Associated Hypercoagulability (Trousseau Syndrome)Migratory superficial thrombophlebitis and acute thromboembolic events occurring in the setting of occult or overt visceral malignancy. Negative for lupus anticoagulant and specific aCL/anti-$\beta_2$GPI serologies 3.

Management & Treatment Protocol

  • Initial Stabilization & Resuscitation: Immediate hospital admission for acute thrombotic events (e.g., deep vein thrombosis, pulmonary embolism, stroke, or acute coronary syndrome). Administer therapeutic parenteral anticoagulation promptly unless active major bleeding precludes it. For catastrophic antiphospholipid syndrome (CAPS), transfer immediately to an intensive care unit for hemodynamic monitoring, mechanical ventilation support, and emergency rescue therapy 2, 7.
  • First-Line Medical / Pharmacological Therapy (with exact adult dosing):
    • Unprovoked Venous Thromboembolism: Long-term oral anticoagulation with warfarin targeting a therapeutic international normalized ratio (INR) of 2.0 to 3.0. Note: Direct oral anticoagulants (DOACs, such as rivaroxaban 20 mg PO daily) are contraindicated in high-risk patients (especially triple-positive APS) due to significantly increased recurrence rates compared to vitamin K antagonists 2, 4.
    • Recurrent Thrombosis Despite Therapeutic INR: Increase target INR to 3.0 to 3.5, or add low-dose aspirin (81 to 100 mg PO daily), or switch to adjusted-dose low-molecular-weight heparin (e.g., enoxaparin 1 mg/kg subcutaneously every 12 hours) 2.
    • Obstetric Antiphospholipid Syndrome: Pre-conceptional counseling and initiation of low-dose aspirin (81 to 100 mg PO daily) prior to conception or immediately upon pregnancy confirmation, combined with prophylactic low-molecular-weight heparin (e.g., enoxaparin 40 mg subcutaneously once daily) throughout gestation and continuing for 6 weeks postpartum in women with prior pregnancy loss. In women with prior thrombosis, therapeutic-dose LMWH is utilized 2, 6.
    • Catastrophic APS (CAPS): Emergency triple therapy combining therapeutic anticoagulation (unfractionated heparin infusion adjusted to maintain aPTT 1.5–2.5 times control), high-dose intravenous glucocorticoids (methylprednisolone 1 g IV daily for 3 consecutive days), and plasma exchange (daily for 3–5 sessions) or intravenous immunoglobulins (IVIG 400 mg/kg/day IV for 5 consecutive days). Additional biologic therapy with rituximab (375 mg/m^2 IV weekly for 4 doses) or eculizumab may be used in refractory cases 7.
  • Surgical / Interventional Indications: Mechanical thrombectomy, catheter-directed thrombolysis, or surgical embolectomy for acute life- or limb-threatening arterial or massive venous thromboses refractory to medical therapy alone, performed under adequate anticoagulation cover 2.

Complications & Prognosis

  • Recurrent Thromboembolic Events: Risk of recurrent arterial or venous thrombosis remains high without life-long, tightly monitored anticoagulation, contributing to significant long-term morbidity and mortality 2, 4.
  • Post-Thrombotic Syndrome & Chronic Thromboembolic Pulmonary Hypertension: Long-term sequelae of lower extremity deep vein thrombosis and recurrent pulmonary emboli leading to chronic vascular obstruction, exercise intolerance, and right heart failure 2.
  • Obstetric Complications: Recurrent spontaneous abortions, severe intrauterine growth restriction, preterm delivery, and maternal pre-eclampsia or HELLP syndrome, which can be successfully mitigated with coordinated multidisciplinary obstetric-rheumatologic care 6.
  • End-Stage Renal Disease: Resulting from progressive APS nephropathy characterized by vaso-occlusive renal lesions, microvascular thrombosis, and glomerulosclerosis 2, 5.
  • Catastrophic Mortality: Despite aggressive intensive care management and triple therapy, catastrophic antiphospholipid syndrome carries a historically high mortality rate ranging between 30% and 50%, primarily driven by multi-organ failure and acute respiratory distress syndrome 7.